Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues |
| Impax Generics | 549.1 | 606.3 | 710.9 | 549.1 | 398.3 | | | |
| Impax Specialty Pharma | 226.7 | 218.1 | 149.5 | 47.0 | 113.2 | | | |
| Global Pharmaceuticals Division | | | | | | 448.7 | 491.7 | 864.7 |
| |
| EBIT |
| Impax Generics | -265.2 | -386.4 | 169.5 | 225.2 | 68.9 | | | |
| Impax Specialty Pharma | -17.5 | 12.1 | 19.3 | -57.5 | -17.6 | | | |
| Global Pharmaceuticals Division | | | | | | 145.6 | 184.0 | 471.2 |
| |
| Mix |
| Impax Generics | 70.8% | 73.5% | 82.6% | 92.1% | 77.9% | | | |
| Impax Specialty Pharma | 29.2% | 26.5% | 17.4% | 7.9% | 22.1% | | | |
| Global Pharmaceuticals Division | | | | | | 77.1% | 95.9% | 98.3% |
| |
| Growth |
| Impax Generics | -9.4% | -14.7% | 29.5% | 37.8% | | | | |
| Impax Specialty Pharma | 3.9% | 45.9% | 218.4% | -58.5% | | | | |
| Global Pharmaceuticals Division | | | | | | -8.8% | -43.1% | 150.7% |
|